Cannabidiol: Difference between revisions

In November 2019, the FDA issued concerns about the safety of cannabidiol, stating that CBD use has potential to cause [[liver injury]], interfere with the mechanisms of [[prescription drug]]s, produce [[gastrointestinal disorder]]s,<ref name=":4">{{Citation | url=https://deliverymeds.ca/cbd-and-gut-disorders/| title=CBD and Gut Disorders| newspaper=| date= 2020-07-24| accessdate=2020-08-24}}</ref> or affect [[alertness]] and [[mood (psychology)|mood]].<ref name="fda11-26-19" /> In October 2020, the FDA updated its safety concerns about CBD,<ref name=fdareg/> acknowledging the unknown effects of protracted use, how it affects the developing brain, fetus or infants during breastfeeding, whether it interacts with [[dietary supplement]]s or [[prescription drug]]s, whether [[male fertility]] is affected, and its possible [[side effect]]s, such as [[Somnolence|drowsiness]].<ref name="hahn">{{cite web | first1 = Stephen M. | last1 = Hahn | name-list-style = vanc |author-link1= Stephen Hahn (oncologist) |title=FDA Advances Work Related to Cannabidiol Products with Focus on Protecting Public Health, Providing Market Clarity |url=https://www.fda.gov/news-events/press-announcements/fda-advances-work-related-cannabidiol-products-focus-protecting-public-health-providing-market |publisher=US Food and Drug Administration |access-date=6 March 2020 |date=5 March 2020}}</ref>